• Zongertinib 60mg

Zongertinib 60mg

SKU:52416

Zongertinib is used for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumour has an HER2 or ERBB2 tyrosine kinase domain activating mutation shown by an authorised test.

Usual adult dose range: 120mg to 180mg once daily based on body weight, usually 120mg once daily for people under 90kg and 180mg once daily for people 90kg or more.


Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.


  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.